About MedImmune
MedImmune is a company based in Gaithersburg (United States) founded in 1987 was acquired by Astrazeneca in April 2007.. MedImmune has completed 5 acquisitions, including Allozyne, AlphaCore Pharma and Cellective Therapeutics. MedImmune operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter Gaithersburg, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$354.18 K (USD), Grant
Sep 01, 2018
-
Investors
Astrazeneca
& 1 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Allozyne
& 4 more
-
Acquired by
Astrazeneca
(Apr 23, 2007)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
403 people
Software Development Team
205 people
Product Management Team
76 people
Data Analysis and Operations Team
68 people
Senior Team
67 people
Human Resources and Administration
63 people
Sales and Marketing
54 people
Operations Team
50 people
Unlock access to complete
Funding Insights of MedImmune
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $354,179
-
First Round
First Round
(01 Jan 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2018 | Amount | Grant - MedImmune | Valuation |
investors |
|
| Mar, 2017 | Amount | Grant - MedImmune | Valuation |
investors |
|
| Jan, 2017 | Amount | Grant - MedImmune | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in MedImmune
MedImmune has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Astrazeneca and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by MedImmune
MedImmune has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Allozyne, AlphaCore Pharma and Cellective Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops protein therapeutics for treating cardiovascular diseases like atherosclerosis.
|
2007 | ||||
|
Protein therapeutics for CNS diseases like multiple sclerosis are developed.
|
2005 | ||||
|
B cell research for cancer and autoimmune diseases was conducted.
|
2003 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - MedImmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Medimmune Comparisons
Competitors of MedImmune
MedImmune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Medimmune
Frequently Asked Questions about MedImmune
When was MedImmune founded?
MedImmune was founded in 1987 and raised its 1st funding round 29 years after it was founded.
Where is MedImmune located?
MedImmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of MedImmune?
Speck Loe is the current CEO of MedImmune.
What does MedImmune do?
MedImmune is a global biologic RD company developing product candidates for three therapeutic areas namely oncology; respiratory, inflammation and autoimmune; and cardiovascular and metabolic disease. It was founded as Molecular Vaccines and has developed Flumist, a nasal spray influenza vaccine which was approved by FDA as a needle-free vaccine CAIV-T in 2007. In April 2007, AstraZeneca acquired MedImmune and since then it is working as its RD unit. In September 2009, MedImmune received approval from the U.S. FDA for its intranasal novel H1N1 influenza vaccine. Currently, it claims to have more than 120 biologics in RD and 40 products in clinical development.
Who are the top competitors of MedImmune?
MedImmune's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
How many acquisitions has MedImmune made?
MedImmune has made 5 acquisitions, including Allozyne, AlphaCore Pharma, and Cellective Therapeutics.
Who are MedImmune's investors?
MedImmune has 2 investors. Key investors include Astrazeneca, and European Union.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.